TY  - JOUR
A1  - Kirsten, Natalia
A1  - Ohm, Frenz
A1  - Gehrdau, Kathrin
A1  - Girbig, Gefion
A1  - Stephan, Brigitte
A1  - Ben-Anaya, Nesrine
A1  - Pinter, Andreas
A1  - Bechara, Falk G.
A1  - Presser, Dagmar
A1  - Zouboulis, Christos C.
A1  - Augustin, Matthias
T1  - Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
JF  - Life
N2  - Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.
KW  - hidradenitis suppurativa
KW  - biologics
KW  - TNF alpha
KW  - adverse drug reaction
KW  - biosimilar
KW  - drug effectiveness
KW  - switching
KW  - adalimumab
KW  - registry
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288213
SN  - 2075-1729
VL  - 12
IS  - 10
ER  - 
TY  - JOUR
A1  - Vaiopoulos, Aristeidis G.
A1  - Kanakis, Meletios A.
A1  - Kapsimali, Violetta
A1  - Vaiopoulos, Georgios
A1  - Kaklamanis, Phedon G.
A1  - Zouboulis, Christos C.
T1  - Juvenile Adamantiades-Behçet disease
JF  - Dermatology
N2  - Adamantiades-Behçet disease (ABD) is a chronic, multisystemic, recurrent, inflammatory vascular disorder of unknown etiology. Patients with symptoms initially appearing at the age of 16 or less are considered as cases of juvenile-onset ABD (JABD). JABD is relatively rare compared to ABD of adults, and only case reports and case studies have been published regarding this subtype of the disease. Epidemiology, clinical features, diagnosis and treatment of JABD are discussed in this review.
KW  - Aphthae
KW  - Childhood
KW  - Epidemiological study
KW  - Genitoanal region
KW  - Adamantiades-Behçet disease
KW  - Behçet’s disease
KW  - Uveitis
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196616
SN  - 1018-8665
SN  - 1421-9832
N1  - This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
VL  - 232
IS  - 2
SP  - 129
EP  - 136
ER  -